St. Jude (STJ) Lower; New Preliminary Data Showing Riata Did Not Prevent Durata Insulation Abrasions
Tweet Send to a Friend
Get Alerts STJ Hot Sheet
Price: $47.04 +0.68%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 4.3%
EPS Growth %: +7.0%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 4.3%
EPS Growth %: +7.0%
Trade STJ Now!
St. Jude Medical (NYSE: STJ) is heading lower Tuesday morning following publication of a new research report for its Durata ICD.
Specifically, the study was conducted by Dr. Robert Houser and focused on Durata lead failures. Houser cautions that data is preliminary and hypothesis generating and additional studies are needed.
The conclusion from the study is that Durata leads failed due to insulation abrasions. Riata ST Optim did not prevent the abrasions, which Houser and his team said developed under 4 years after implant.
For more on the publication, click here.
The report comes following headlines last week that the FDA was going to order a review of Riata Defibrillator leads. Shares of St. Jude are down about 0.2 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Specifically, the study was conducted by Dr. Robert Houser and focused on Durata lead failures. Houser cautions that data is preliminary and hypothesis generating and additional studies are needed.
The conclusion from the study is that Durata leads failed due to insulation abrasions. Riata ST Optim did not prevent the abrasions, which Houser and his team said developed under 4 years after implant.
For more on the publication, click here.
The report comes following headlines last week that the FDA was going to order a review of Riata Defibrillator leads. Shares of St. Jude are down about 0.2 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Echo Therapeutics (ECTE) Gets IRB Approval for Symphony CGM System
- Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
Create E-mail Alert Related Categories
FDA, Insiders' Blog
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
